Intuitive Invests.Gp - Light Science Technologies - Intention To Float

Intuitive Investments

12/10/2021 09:48

RNS Number : 7971O

Intuitive Investments Group plc

12 October 2021

 

Intuitive Investments Group plc

 

Light Science Technologies Holdings plc's Intention To Float Announcement

 

Intuitive Investments Group plc (AIM: IIG) ("IIG" or the "Company"), a closed-end investment company focussed on the life sciences sector, notes the intention to float announcement, released today by Light Science Technologies Holdings plc ("LSTH"), in relation to the proposed admission of LSTH's ordinary shares to trading on AIM ("Admission").

 

IIG's investment in LSTH consists of £1 million of convertible loan notes, which have a 7.25% coupon and will convert automatically at a 20% discount to LSTH's ordinary share price at Admission. IIG has also subscribed for an amount of ordinary shares equal to the interest and non-executive directors' fees due up to the date of Admission of £78,000 in the conditional placing associated with the flotation. IIG expects to receive, in aggregate, 13,280,000 ordinary shares in LSTH, representing 7.6% of its issued share capital on Admission. Admission is expected to take place on 15 October 2021.

 

LSTH was IIG's first investment from its pipeline of opportunities, following its successful IPO and Admission to AIM in December 2020.

 

For further information, please contact:

 

Intuitive Investments Group plc
www.iigplc.com
David Evans, Executive Chairman
Robert Naylor, CEO
Via Walbrook PR
Strand Hanson Limited - Nominated Adviser
+44 (0) 20 7409 3494
James Dance / James Bellman
Turner Pope Investments (TPI) Ltd - Broker
+44 (0) 20 3657 0050
Andrew Thacker / James Pope
Walbrook PR Limited - Media & Investor Relations
+44 (0)20 7933 8780 or intuitive@walbrookpr.com
Paul McManus
+44 (0) 7980 541 893

 

 

About Intuitive Investments Group plc

The Company is a recently established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders.  

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
MSCDZMMGRZGGMZG